Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Tóm tắt
Từ khóa
Tài liệu tham khảo
Schneider, 2007, Mixed brain pathologies account for most dementia cases in community-dwelling older persons, Neurology, 69, 2197, 10.1212/01.wnl.0000271090.28148.24
White, 2005, Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study, J Geriatr Psychiatry Neurol, 18, 224, 10.1177/0891988705281872
Knopman, 2003, Neuropathology of cognitively normal elderly, J Neuropathol Exp Neurol, 62, 1087, 10.1093/jnen/62.11.1087
Price, 1999, Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease, Ann Neurol, 45, 358, 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
Petersen, 2004, Mild cognitive impairment as a diagnostic entity, J Intern Med, 256, 183, 10.1111/j.1365-2796.2004.01388.x
Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3
Chetelat, 2003, Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?, Neurology, 60, 1374, 10.1212/01.WNL.0000055847.17752.E6
Jack, 1999, Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment, Neurology, 52, 1397, 10.1212/WNL.52.7.1397
Yuan, 2009, Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment; a meta-analysis, AJNR Am J Neuroradiol, 30, 404, 10.3174/ajnr.A1357
Mattsson, 2009, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, 302, 385, 10.1001/jama.2009.1064
Jagust, 1996, Functional imaging predicts cognitive decline in Alzheimer's disease, J Neuroimaging, 6, 156, 10.1111/jon199663156
Visser, 2009, Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, Lancet Neurol, 8, 619, 10.1016/S1474-4422(09)70139-5
McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939
Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994
Klein, 2004, Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease, Neurobiol Aging, 25, 569, 10.1016/j.neurobiolaging.2004.02.010
Oddo, 2006, Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology, J Biol Chem, 281, 1599, 10.1074/jbc.M507892200
Gomez-Isla, 1997, Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease, Ann Neurol, 41, 17, 10.1002/ana.410410106
Bennett, 2004, Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function, Arch Neurol, 61, 378, 10.1001/archneur.61.3.378
Terry, 1991, Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann Neurol, 30, 572, 10.1002/ana.410300410
Hampel, 2008, Core candidate neurochemical and imaging biomarkers of Alzheimer's disease, Alzheimers Dement, 4, 38, 10.1016/j.jalz.2007.08.006
Shaw, 2007, Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics, Nat Rev Drug Discov, 6, 295, 10.1038/nrd2176
Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009
Rowe, 2007, Imaging beta-amyloid burden in aging and dementia, Neurology, 68, 1718, 10.1212/01.wnl.0000261919.22630.ea
Edison, 2007, Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study, Neurology, 68, 501, 10.1212/01.wnl.0000244749.20056.d4
Ikonomovic, 2008, Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease, Brain, 131, 1630, 10.1093/brain/awn016
Bacskai, 2007, Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report, Arch Neurol, 64, 431, 10.1001/archneur.64.3.431
Rosen, 2009, Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease, Acta Neuropathol
Clark, 2003, Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?, Arch Neurol, 60, 1696, 10.1001/archneur.60.12.1696
Strozyk, 2003, CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology, 60, 652, 10.1212/01.WNL.0000046581.81650.D0
Schoonenboom, 2008, CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease, Neurobiol Aging, 29, 669, 10.1016/j.neurobiolaging.2006.11.018
Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans, Ann Neurol, 59, 512, 10.1002/ana.20730
Jagust, 2009, Relationships between biomarkers in aging and dementia, Neurology, 73, 1193, 10.1212/WNL.0b013e3181bc010c
Grimmer, 2009, Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid, Biol Psychiatry, 65, 927, 10.1016/j.biopsych.2009.01.027
Tolboom, 2009, Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding, J Nucl Med, 50, 1464, 10.2967/jnumed.109.064360
Buerger, 2006, CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, Brain, 129, 3035, 10.1093/brain/awl269
Shaw, 2009, Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Ann Neurol, 65, 403, 10.1002/ana.21610
Hesse, 2001, Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci Lett, 297, 187, 10.1016/S0304-3940(00)01697-9
Ost, 2006, Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury, Neurology, 67, 1600, 10.1212/01.wnl.0000242732.06714.0f
Arai, 1995, Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease, Ann Neurol, 38, 649, 10.1002/ana.410380414
Blennow, 1995, Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?, Mol Chem Neuropathol, 26, 231, 10.1007/BF02815140
Tapiola, 1997, The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease, Neuroreport, 8, 3961, 10.1097/00001756-199712220-00022
Bian, 2008, CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, 70, 1827, 10.1212/01.wnl.0000311445.21321.fc
Grossman, 2005, Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease, Ann Neurol, 57, 721, 10.1002/ana.20477
Ballatore, 2007, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders, Nat Rev Neurosci, 8, 663, 10.1038/nrn2194
Schwartz, 1979, Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat, Science, 205, 723, 10.1126/science.462184
Attwell, 2001, An energy budget for signaling in the grey matter of the brain, J Cereb Blood Flow Metab, 21, 1133, 10.1097/00004647-200110000-00001
Rocher, 2003, Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons, Neuroimage, 20, 1894, 10.1016/j.neuroimage.2003.07.002
Jagust, 2007, What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?, Neurology, 69, 871, 10.1212/01.wnl.0000269790.05105.16
Ibanez, 1998, Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease, Neurology, 50, 1585, 10.1212/WNL.50.6.1585
Minoshima, 1997, Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease, Ann Neurol, 42, 85, 10.1002/ana.410420114
Hoffman, 2000, FDG PET imaging in patients with pathologically verified dementia, J Nucl Med, 41, 1920
Petrie, 2009, Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings, Arch Neurol, 66, 632, 10.1001/archneurol.2009.59
Bobinski, 2000, The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease, Neuroscience, 95, 721, 10.1016/S0306-4522(99)00476-5
Jack, 1992, MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease, Neurology, 42, 183, 10.1212/WNL.42.1.183
Fox, 1999, Correlation between rates of brain atrophy and cognitive decline in AD, Neurology, 52, 1687, 10.1212/WNL.52.8.1687
Jack, 2002, Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia, Neurology, 58, 750, 10.1212/WNL.58.5.750
Silbert, 2003, Changes in premorbid brain volume predict Alzheimer's disease pathology, Neurology, 61, 487, 10.1212/01.WNL.0000079053.77227.14
Braak, 1991, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol, 82, 239, 10.1007/BF00308809
Whitwell, 2008, MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study, Neurology, 71, 743, 10.1212/01.wnl.0000324924.91351.7d
Ingelsson, 2004, Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain, Neurology, 62, 925, 10.1212/01.WNL.0000115115.98960.37
Jack, 2009, Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease, Brain, 132, 1355, 10.1093/brain/awp062
Mintun, 2006, [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease, Neurology, 67, 446, 10.1212/01.wnl.0000228230.26044.a4
Aizenstein, 2008, Frequent amyloid deposition without significant cognitive impairment among the elderly, Arch Neurol, 65, 1509, 10.1001/archneur.65.11.1509
Peskind, 2006, Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition, Arch Neurol, 63, 936, 10.1001/archneur.63.7.936
Bouwman, 2009, CSF biomarker levels in early and late onset Alzheimer's disease, Neurobiol Aging, 30, 1895, 10.1016/j.neurobiolaging.2008.02.007
Fagan, 2007, Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults, Arch Neurol, 64, 343, 10.1001/archneur.64.3.noc60123
Fagan, 2009, Decreased cerebrospinal fluid Aβ(42) correlates with brain atrophy in cognitively normal elderly, Ann Neurol, 65, 176, 10.1002/ana.21559
Li, 2007, CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, 69, 631, 10.1212/01.wnl.0000267428.62582.aa
Gustafson, 2007, Cerebrospinal fluid beta-amyloid 1–42 concentration may predict cognitive decline in older women, J Neurol Neurosurg Psychiatry, 78, 461, 10.1136/jnnp.2006.100529
Stomrud, 2007, Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly, Dement Geriatr Cogn Disord, 24, 118, 10.1159/000105017
Braak, 1997, Frequency of stages of Alzheimer-related lesions in different age categories, Neurobiol Aging, 18, 351, 10.1016/S0197-4580(97)00056-0
Chetelat, 2002, Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment, Neuroreport, 13, 1939, 10.1097/00001756-200210280-00022
Ewers, 2007, Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI, Neurology, 69, 2205, 10.1212/01.wnl.0000286944.22262.ff
Sluimer, 2008, Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study, Neurobiol Aging
de Leon, 2001, Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET), Proc Natl Acad Sci USA, 98, 10966, 10.1073/pnas.191044198
Jagust, 2006, Brain imaging evidence of preclinical Alzheimer's disease in normal aging, Ann Neurol, 59, 673, 10.1002/ana.20799
Fox, 1999, Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease, Lancet, 353, 2125, 10.1016/S0140-6736(99)00496-1
Jack, 2004, Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD, Neurology, 62, 591, 10.1212/01.WNL.0000110315.26026.EF
Kaye, 1997, Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia, Neurology, 48, 1297, 10.1212/WNL.48.5.1297
Engler, 2006, Two-year follow-up of amyloid deposition in patients with Alzheimer's disease, Brain, 129, 2856, 10.1093/brain/awl178
Josephs, 2008, Beta-amyloid burden is not associated with rates of brain atrophy, Ann Neurol, 63, 204, 10.1002/ana.21223
Jack, 2008, 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment, Brain, 131, 665, 10.1093/brain/awm336
Mormino, 2009, Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects, Brain, 132, 1310, 10.1093/brain/awn320
Frisoni, 2009, In vivo mapping of amyloid toxicity in Alzheimer disease, Neurology, 72, 1504, 10.1212/WNL.0b013e3181a2e896
De Santi, 2001, Hippocampal formation glucose metabolism and volume losses in MCI and AD, Neurobiol Aging, 22, 529, 10.1016/S0197-4580(01)00230-5
Reiman, 1998, Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease, Ann Neurol, 44, 288, 10.1002/ana.410440226
Vemuri, 2009, MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations, Neurology, 73, 287, 10.1212/WNL.0b013e3181af79e5
Sunderland, 1999, Longitudinal stability of CSF tau levels in Alzheimer patients, Biol Psychiatry, 46, 750, 10.1016/S0006-3223(99)00143-2
Bouwman, 2007, Longitudinal changes of CSF biomarkers in memory clinic patients, Neurology, 69, 1006, 10.1212/01.wnl.0000271375.37131.04
Vemuri, 2009, MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change, Neurology, 73, 294, 10.1212/WNL.0b013e3181af79fb
Fox, 1997, Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease, J Magn Reson Imaging, 7, 1069, 10.1002/jmri.1880070620
Chan, 2003, Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study, Lancet, 362, 1121, 10.1016/S0140-6736(03)14469-8
Ridha, 2006, Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study, Lancet Neurol, 5, 828, 10.1016/S1474-4422(06)70550-6
Wahlund, 2003, Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients, Neurosci Lett, 339, 99, 10.1016/S0304-3940(02)01483-0
Whitwell, 2007, 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease, Brain, 130, 1777, 10.1093/brain/awm112
Stern, 2006, Cognitive reserve and Alzheimer disease, Alzheimer Dis Assoc Disord, 20, S69, 10.1097/00002093-200607001-00010
Nelson, 2008, Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons, Brain Pathol
Holmes, 2008, Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 372, 216, 10.1016/S0140-6736(08)61075-2
Petersen, 2010, Alzheimer's disease: progress in prediction, Lancet Neurol, 9, 4, 10.1016/S1474-4422(09)70330-8
Edison, 2008, Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study, Neurobiol Dis, 32, 412, 10.1016/j.nbd.2008.08.001
Ross, 1998, In vivo MR spectroscopy of human dementia, Neuroimaging Clin N Am, 8, 809
Duyckaerts, 1997, Prevalence, incidence and duration of Braak's stages in the general population: can we know?, Neurobiol Aging, 18, 362, 10.1016/S0197-4580(97)00047-X
Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443
Reiman, 2004, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia, Proc Natl Acad Sci USA, 101, 284, 10.1073/pnas.2635903100
Scarmeas, 2003, APOE genotype and cerebral blood flow in healthy young individuals, JAMA, 290, 1581, 10.1001/jama.290.12.1581
Ghebremedhin, 1998, High frequency of apolipoprotein E ɛ4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes, Exp Neurol, 153, 152, 10.1006/exnr.1998.6860
Reiman, 2009, Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, Proc Natl Acad Sci USA, 106, 6820, 10.1073/pnas.0900345106
Roses, 1994, Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease, J Neuropathol Exp Neurol, 53, 429, 10.1097/00005072-199409000-00002
Drzezga, 2009, Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease, Neurology, 72, 1487, 10.1212/WNL.0b013e3181a2e8d0
Harold, 2009, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nat Genet, 41, 1088, 10.1038/ng.440
Lambert, 2009, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, Nat Genet, 41, 1094, 10.1038/ng.439
Buckner, 2005, Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory, J Neurosci, 25, 7709, 10.1523/JNEUROSCI.2177-05.2005
Sperling, 2009, Amyloid deposition is associated with impaired default network function in older persons without dementia, Neuron, 63, 178, 10.1016/j.neuron.2009.07.003